US Patent Issued to Oregon Health & Science University on Aug. 26 for "Second generation inhibitors of mitochondrial permeability transition pore with improved plasma stability" (American, Italian Inventors)

ALEXANDRIA, Va., Aug. 26 -- United States Patent no. 12,398,110, issued on Aug. 26, was assigned to Oregon Health & Science University (Portland, Ore.).

"Second generation inhibitors of mitochondrial permeability transition pore with improved plasma stability" was invented by Michael Cohen (Portland, Ore.), Michael Forte (Portland, Ore.), Justina Sileikyte (Portland, Ore.), Aaron Nilsen (Portland, Ore.), Jordan Devereaux (Portland, Ore.) and Paolo Bernardi (Padua, Italy).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides compounds useful as mitochondrial permeability transition pore (mtPTP) inhibitors, the compounds being of Formula (I), or a pharmaceutically acceptable salt thereof...